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Psychological distress, iron deficiency,
active disease and female gender are
independent risk factors for fatigue
in patients with ulcerative colitis
Bo¨rje Jonefja¨ll1,2, Magnus Simre´n1,3, Anders Lasson4, Lena O¨hman1,5,6
and Hans Strid1,4
Abstract
Background: Patients with ulcerative colitis often report fatigue.
Objectives: To investigate prevalence of and risk factors for fatigue in patients with ulcerative colitis with active disease and
during deep remission.
Methods: In this cross-sectional study, disease activity was evaluated with endoscopy and calprotectin, and patients were
classified as having active disease (n¼ 133) or being in deep remission (n¼ 155). Blood samples were analysed to assess
anaemia, iron deficiency and systemic immune activity. Patients completed questionnaires to assess fatigue, psychological
distress, gastrointestinal symptoms and quality of life.
Results: The prevalence of high fatigue (general fatigue 13, Multidimensional Fatigue Inventory) was 40% in the full study
population. Among patients with high fatigue, female gender and iron deficiency were more prevalent, and these patients
had more severe disease activity and reported higher levels of anxiety, depression and decreased quality of life compared
with patients with no/mild fatigue. A logistic regression analysis identified probable psychiatric disorder (odds ratio (OR)
(confidence interval) 6.1 (3.1–12.2)), iron deficiency (OR 2.5 (1.2–5.1)), active disease (OR 2.2 (1.2–3.9)) and female gender
(OR 2.1 (1.1–3.7)) as independent risk factors for high fatigue. Similar results were found concerning psychological distress,
gender and quality of life, but immune markers did not differ in patients in deep remission with high vs. no/mild fatigue.
Conclusions: Probable psychiatric disorder, iron deficiency, active disease and female gender are independent risk factors for
high fatigue in patients with ulcerative colitis. Low-grade immune activity does not seem to be the cause of fatigue among
patients in deep remission.
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Introduction
Fatigue is a common clinical feature among patients
with chronic inflammatory diseases, including inflam-
matory bowel disease (IBD). The prevalence of fatigue
has been reported to be 21–41% in patients with IBD
with inactive disease1–6 and as high as 70–75% in
patients with active disease.1,5 Fatigue is associated
with reduced health-related quality of life, and effective
management options are lacking.3–5,7–9 Moreover, fati-
gue is a complex symptom with both physical and
mental components.10 Disease activity, psychological
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distress, perceived stress, quality of sleep and female
gender have all been correlated with high levels of fati-
gue,1,4–6,11–13 while factors important for fatigue among
IBD patients with inactive disease are not fully under-
stood. Further, anaemia and iron deficiency have been
suggested as important contributing factors to fatigue.
However, existing data concerning the association
between anaemia and fatigue in IBD are conflict-
ing,2,4,6,13 and previous studies have reported no correl-
ation between fatigue and iron deficiency in IBD
patients,6,12,13 but the measurement and definition of
iron deficiency in patients with IBD are problematic.
Serological markers for iron deficiency, such as ferritin
and transferrin saturation, are affected by inflamma-
tion. Therefore, use of several markers in combination
has been suggested to provide the most reliable assess-
ment of iron deficiency in IBD,14,15 which has been
taken into account in this study.
Low-grade immune activity might also be a factor
of importance for fatigue in IBD, since patients with
different chronic inflammatory conditions report high
levels of fatigue.3,16 Chronic fatigue syndrome is a
multidimensional condition characterized by chronic,
disabling fatigue and various other somatic symp-
toms.17 The pathogenesis and pathophysiology of
this syndrome are unknown, but post-infectious
immune alterations have been proposed as a plausible
explanation.17 A systematic review reported that 51%
of patients with chronic fatigue syndrome have co-
existing irritable bowel syndrome (IBS),18 and post-
infectious low-grade immune activity is considered to
be a potential contributing factor to symptom gener-
ation in IBS.19 Among patients with IBS, fatigue is a
common symptom, which is associated with gastro-
intestinal symptom severity and psychological dis-
tress.20 Further, IBS-like symptoms during remission
among patients with IBD are common21,22 and have
been associated with higher levels of fatigue, suggest-
ing possible common pathophysiological path-
ways.23,24 Low-grade immune activity during
remission has not been studied previously as a poten-
tial risk factor for fatigue among patients with ulcera-
tive colitis (UC).
We hypothesized that disease activity, psychological
distress, anaemia and iron deficiency are all associated
with fatigue in patients with UC. Further, we also
hypothesized that low-grade immune activity and
residual gastrointestinal symptoms contribute to fati-
gue among patients with UC in deep remission.
Therefore, our aim was to investigate the preva-
lence of high fatigue in a large cohort of patients
with UC with active disease and in deep remis-
sion, and to determine factors associated with
fatigue in UC.
Materials and methods
Study design
Patients with UC (n¼ 298) were recruited from four
specialized IBD clinics in the Va¨stra Go¨taland
Region, Sweden. The criteria for inclusion were verified
diagnosis of UC in patients between 18 and 75 years old
according to Lennard-Jones criteria.25 Patients with
malignancy within the previous 5 years, difficulties in
understanding the Swedish language, abuse of alcohol
or drugs, previous surgery with resection of colon or
small intestine, celiac disease, or significant heart, lung,
kidney, neurological, rheumatic or psychiatric disease
were excluded. The study was approved by the
Regional Ethical Review Board in Gothenburg, and
the subjects gave verbal and written informed consent
before participation.
The patients were recruited to the study at a regular
outpatient-clinic visit between September 2012 and
April 2014. Blood and stool samples were collected
and stored at 80C and 20C, respectively. The
patients completed self-administrated questionnaires
and were examined by a physician. The examination
included a rigid sigmoidoscopy. Patients with faecal
calprotectin >200 mg/g and normal rectal mucosa at
the initial endoscopic investigation were further exam-
ined with a flexible sigmoidoscopy within 2 weeks to
determine inflammatory activity of the colonic mucosa
(Figure 1).
Inflammatory activity
Clinical disease activity. At the study visit, the disease
activity was evaluated using the Mayo score.26 The
Mayo score contains four variables: stool frequency,
rectal bleeding, endoscopic finding and the physician’s
global assessment. Each variable is graded from 0 to 3,
and the maximum total score is 12, with higher score
indicating more severe disease. The initial endoscopic
score, the physician’s global assessment and the total
Mayo score were adjusted in the patients who under-
went flexible sigmoidoscopy if macroscopic inflamma-
tion was detected (Figure 1). Disease activity was
graded as follows using the Mayo score: severe disease
10–12 points, moderate disease 6–9 points, mild disease
3–5 points and remission 0–2 points with no subscore
>1.26 The patients were classified as having active dis-
ease or being in deep remission. To the best of our
knowledge, criteria for the term ‘‘deep remission’’
have not yet been established.27 In this study, deep
remission was defined as a relapse-free period of 3
months prior to inclusion and a total Mayo score 2,
provided the scores for physician’s global assessment,
rectal bleeding and the endoscopic subscore were all 0.
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The colonic extent of the disease was determined
according to the Montreal classification,28 and the
most proximal extent of macroscopic inflammation
since diagnosis was recorded.
Inflammatory biomarkers. Faecal calprotectin was used as
a marker for mucosal inflammation 29 and was ana-
lysed using a sandwich enzyme-linked immunosorbent
assay (Calprotectin ELISA; Bu¨hlmann Laboratories
AG, Basel, Switzerland) with a monoclonal capture
antibody specific for calprotectin, according to the
manufacturer’s instructions. The inter-assay coefficient
of variation was <15% and the sensitivity of the assay
was <10 mg/g. In the general population, the normal
level is <50 mg/g. Furthermore, high sensitive C-reac-
tive peptide (hs-CRP), a systemic inflammatory marker,
was analysed by enzyme-linked immunosorbent
assay (ELISA) as a routine test at the clinical immun-
ology laboratory at Sahlgrenska University Hospital.
Additionally, as markers for systemic immune
activity, the levels of interleukin (IL) 12p70 and inter-
feron (IFN)-g (reflecting T helper 1 cell-mediated
activity), IL-4, IL-13 and IL-10 (reflecting T helper 2
cell-mediated activity), and IL-17A (reflecting T helper
17 cell-mediated activity) were measured. Further,
IL-1b, IL-6, IL-8 and tumour necrosis factor (TNF)-a
(mainly reflecting activity of the innate immune
system) in serum samples were measured. Samples
were measured using the Meso Scale Discovery
(MSD) platform (MSD, Rockville, MD). All analyses
were performed according to the manufacturers’
instructions.
Anaemia and iron deficiency
Anaemia was defined as haemoglobin< 12.0 g/dL
(female) or <13.0 g/dL (male) in accordance with
European Crohn’s and Colitis Organisation (ECCO)
guidelines 2015.14 To assess iron deficiency, levels of
ferritin, transferrin saturation and soluble transferrin
receptor were analysed in serum as a routine test at
the clinical chemistry laboratory at Sahlgrenska
University Hospital. The definition of iron deficiency
was determined in accordance with current ECCO
guidelines14 (Figure 2).
Questionnaires
Fatigue. The level of fatigue was measured by the
Multidimensional Fatigue Inventory (MFI). The MFI
consists of 20 statements, which cover different aspects
of fatigue. The results are expressed as five domains:
General fatigue, Physical fatigue, Reduced activity,
Reduced motivation and Mental fatigue, with scores
ranging from 4 to 20. General fatigue is the domain
recommended for use as an indicator for fatigue when
only one score is desired.10 Similarly to several previous
studies, ‘high fatigue’ was defined as a General fatigue
Patients with UC (n= 298)
Active disease
 (n=155)
Criteria for deep remission fulfilled
Calprotectin <200 mg/g
Physician evaluation
Rigid sigmoidoscopy
Blood and stool samples
Questionnaires
Flexible sigmoidoscopy
Endoscopic score = 0
No (n = 145)*
No (n = 10)
Deep remission
(n = 133)
Yes (n = 148)*
Yes (n = 128)**
Yes (n = 5)
No (n = 15)
Figure 1. Study flow chart. 298 patients with ulcerative colitis were thoroughly investigated to rule out ongoing macroscopic mucosal
inflammation among the patients classified as deep remission. *Four patients did not complete the MFI questionnaire and one patient
was excluded due to celiac disease. **Five patients did not provide stool samples and were excluded.
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score 13,1,5,6 which is based on the 95th percentile of
the score in a group of healthy controls.3
Psychological distress. The Hospital Anxiety and
Depression scale (HAD) was used to assess psycho-
logical distress. The HAD scale consists of 14 items,
each using a Likert scale (0–3), with subscales for anx-
iety (7 items) and depression (7 items). The results are
expressed as a total score (min–max: 0–42) in this study.
The higher the scores, the more severe are the symp-
toms of anxiety and depression.30 Further, patients can
be classified as having a probable psychiatric disorder
(total HAD 13) or no/possible psychiatric disorder
(total HAD< 13).31
Quality of life. Health-related quality of life was mea-
sured using the Inflammatory Bowel Disease
Questionnaire (IBDQ), which consists of 32 questions,
each using a Likert scale (1–7). The results are
expressed as a total score, range 32–234, with higher
values indicating better quality of life.32,33
Gastrointestinal (GI) symptoms. The severity of GI symp-
toms was assessed using the Gastrointestinal Symptom
Rating Scale (GSRS). The GSRS contains 15 questions
and uses a Likert scale (1–7). The higher the score, the
more pronounced are the symptoms. The results
can be expressed as a total score or be divided into
subdomains (Diarrhoea, Constipation, Abdominal
pain, Indigestion and Reflux).34,35 In this study, the
overall severity of GI symptoms is reported as a total
GSRS score.
The presence of IBS-like symptoms during deep
remission was determined using the Rome III
Diagnostic Questionnaire.36 To fulfil the Rome III cri-
teria for IBS, the patients had to have abdominal dis-
comfort or pain combined with two of the following
three features: (1) relieved with defecation, (2) onset
associated with a change in stool frequency, and
(3) onset associated with a change in form (appearance)
of stool. The symptoms should have been present for at
least 2–3 days per month during the previous 3 months,
and the symptoms should have been present for more
than 6 months.37
Data analysis
The study population was first investigated to determine
the prevalence of high fatigue and characterize the type
of fatigue using the different MFI domains. To investi-
gate the patients with high fatigue and identify possible
risk factors for high fatigue, the UC patients with high
fatigue (MFI General fatigue score 13) were com-
pared with patients with mild/no fatigue (MFI
General fatigue score< 13) concerning demographic
data, disease characteristics, inflammatory disease activ-
ity, anaemia, iron deficiency, psychological distress and
quality of life. Independent risk factors for high fatigue
were then identified using a multivariate logistic regres-
sion analysis. To characterize the fatigue among the
patients with and without these risk factors, each MFI
domain was further analysed. Thereafter, the UC
patients in deep remission with high vs. mild/no fatigue
were compared concerning age, gender, anaemia, iron
Active disease
(n = 155)
Iron deficiency*
(n = 51)
Iron sufficient*
(n = 208)
↑ sTfR or Tsat <16% or
Tsat <20% with ↑ CRP
No
No
No
Yes
Yes
Yes
Normal CRP (<5 mg/L)
Ferritin >30 mg/L
Ferritin
<30 μg/L
Ferritin
30–100 μg/L
Ferritin
>100 μg/L
Deep remission
(n = 133)
Figure 2. Iron status in the patients according to the ECCO guidelines 2015.14
CRP: C-reactive peptide; " sTfR: elevated soluble transferrin receptor; Tsat: Transferrin saturation. *29 patients were not able to classify
due to missing data.
Jonefja¨ll et al. 151
deficiency, psychological distress, quality of life, resi-
dual gastrointestinal symptoms (including prevalence
of IBS-like symptoms) and low-grade inflammatory
activity.
Statistical analysis. Continuous data are expressed as
mean values with standard deviation (SD) for normal
distributed data (Mayo score, MFI, HAD, IBDQ,
GSRS, age and disease duration) and median values
with interquartile range (IQR) for non-normally dis-
tributed data (calprotectin, hs-CRP and cytokines,
where data were strongly skewed). Categorical vari-
ables are expressed as number of patients and percent-
age. Comparisons between two groups were performed
with Student’s t-test for normally distributed continu-
ous data, Mann–Whitney U test for non-normally
distributed continuous data, and Fisher’s exact test
(2-sided) for categorical data. In order to determine
factors independently associated with high fatigue
(‘risk factors’), we performed binary logistic regression
analyses in the cohort with high fatigue (MFI General
fatigue 13) as the dependent variable, and factors uni-
variately associated with high fatigue as independent
variables. A p-value< .05 was considered to be statis-
tically significant. All statistical analyses were per-
formed using the IBM SPSS Statistics 19 software
(SPSS Inc., Chicago, IL, USA).
Results
Characterization of the study population
Demographic data and disease activity. In total, 288 patients
with UC were included in the study and were classified
as having active disease (n¼ 155) or being in deep remis-
sion (n¼ 133) (Figure 1). Age, gender, disease duration,
colonic extension of disease, medical maintenance
treatment and prevalence of primary sclerosing cholan-
gitis among the study population are presented in
Table 1. According to the total Mayo score, among
the patients with active disease, 4% (n¼ 6) had severe
disease, 27% (n¼ 42) moderate disease and 39% (n¼ 61)
mild disease. Among the patients classified as having
active disease, 29% (n¼ 46) were in clinical remission
according to the Mayo score, but did not meet the
study criteria for deep remission due to mild endoscopic
inflammation (endoscopic subscore¼ 1 (n¼ 30)), blood
in the stool (bleeding subscore¼ 1 (n¼ 2)) or a relapse
within 3 months prior to study visit (n¼ 14).
Anaemia and iron deficiency. In total, 5% (n¼ 13) fulfilled
the criteria for anaemia, and iron deficiency was iden-
tified in 20% (n¼ 51) of the patients (Figure 2). Due to
missing data, it was not possible to classify 29 patients
as being iron deficient or not.
Fatigue
The levels of fatigue in the full study population mea-
sured by the MFI domains were (mean (SD)) General
fatigue: 11.1 (4.3); Physical fatigue: 9.9 (4.5); Reduced
activity: 9.5 (4.1); Reduced motivation: 8.3 (3.7) and
Mental fatigue: 8.8 (3.7). The overall prevalence of
high fatigue (MFI General fatigue 13) among the
patients was 40% (n¼ 116).
Comparison between patients with and without high
fatigue. Comparisons between the groups of patients
with high fatigue and no/mild fatigue concerning demo-
graphic data, disease characteristics and medical
treatment are shown in Table 1. The patients with
high fatigue had a lower mean age and a shorter dur-
ation of disease, and female gender was more prevalent
compared with the patients with no/mild fatigue.
However, no differences in current medical treatment
were observed between the two groups. The clinical dis-
ease activity score was higher and iron deficiency, but
not anaemia, was more prevalent among patients with
high fatigue. Moreover, these patients reported poorer
psychological well-being and reduced quality of
life compared with patients with no/mild fatigue
(Table 2). The markers for increased immune activity,
faecal calprotectin and serum IL-17A, were signifi-
cantly higher among the patients reporting high fatigue.
However, hs-CRP and the other cytokines measured in
Table 1. Comparison of demographic data and disease
characteristics in patients with ulcerative colitis (UC) with
high fatigue and no/mild fatigue.
UC high
fatigue
(N¼ 116)
UC no/mild
fatigue
(N¼ 172) p
Years of age, mean
(min–max)
39 (19–69) 44 (18–73) <.01
Female gender, n (%) 61 (52) 55 (32) <.01
Mean disease duration (SD),
years
11 (9) 14 (12) .02
Proctitis/left sided/
extensive, %
18/27/55 18/31/51 .74
Primary sclerosing
cholangitis, n (%)
1 (1) 7 (4) .15
5-ASA, oral, n (%)a 92 (79) 123 (72) .17
5-ASA, topical, n (%)a 7 (6) 3 (2) .10
Thiopurines, n (%)a 23 (20) 30 (17) .64
Anti-TNF-a, n (%)a 9 (8) 7 (4) .20
Corticosteroids, oral, n (%)a 0 (0) 1 (0) 1.00
Corticosteroids, topical, n (%)a 3 (3) 0 (0) .06
aOngoing treatment prior to study visit.
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serum samples did not differ between the two groups
(Table 3). The variables that differed significantly
between the two groups in the initial comparisons
were included in a multivariate logistic regression
analysis. Representing the variables reflecting inflam-
matory activity in the initial comparisons (Mayo
score, faecal calprotectin and IL-17A), the study popu-
lation was dichotomized into those with active disease
and those in deep remission (Figure 1), and this vari-
able was included in the analysis. The population was
dichotomized into clinically applicable psychiatric dis-
tress (probable psychiatric disorder (HAD total 13)
or no/possible psychiatric disorder (HAD total< 13)).
Age, female gender and iron deficiency were also
included in the analysis, but quality of life and disease
duration were not, since they were not considered to be
possible causes of fatigue. The multivariate logistic
regression analysis identified the following independent
risk factors for high fatigue (odds ratio (95% confidence
interval)): probable psychiatric disorder, 6.2 (3.1–12.2);
iron deficiency, 2.5 (1.2–5.1); active disease, 2.2 (1.2–3.9)
and female gender, 2.1 (1.1–3.7), R2¼ 0.32. Age was not
an independent risk factor for high fatigue: 0.98 (0.96–
1.01). The differences in prevalence of high fatigue
among the patients with and without these risk factors
are shown in Figure 3. Further comparisons showed
higher levels of fatigue in all of the MFI domains in
patients with the identified risk factors for high fatigue
(probable psychiatric disorder, iron deficiency, active
disease and female gender (p< .05)) except for mental
fatigue and reduced motivation and activity when com-
paring females and males. Since it is difficult to deter-
mine a cut-off for iron deficiency in patients with IBD,14
a post-hoc analysis was performed to compare patients
with low levels of ferritin (< 30mg/L¼ iron deficiency)
and high levels of ferritin (> 100mg/L¼ iron sufficient)
regardless of disease activity and systemic inflammatory
activity (levels of CRP). This analysis showed that
patients with low levels of ferritin reported higher
levels of fatigue on all MFI domains (p< .01). Further,
high fatigue was more prevalent among patients with
ferritin< 30mg/L compared with patients with fer-
ritin> 100mg/L (66% vs. 31%, p< .001).
Comparison between patients in deep remission with and
without high fatigue. The prevalence of high fatigue
among the patients with UC in deep remission
(n¼ 35, 26%) was further investigated. As observed in
the total study population, female gender was more
common, the degree of psychological distress was
higher, quality of life was reduced and iron deficiency
tended to be more prevalent among the patients in deep
remission with high fatigue than in patients with no/
mild fatigue. Patients in deep remission with high fati-
gue also reported more severe gastrointestinal symp-
toms compared with patients in deep remission with
no/mild fatigue. Further, the proportion of patients
who fulfilled the Rome III criteria for IBS tended to
be larger among patients with high fatigue (Table 4).
To explore the role of low-grade immune activity, the
levels of mucosal and systemic inflammatory markers
were also compared between the UC patients in deep
remission with high fatigue and no/mild fatigue.
However, the patients in deep remission with high fati-
gue did not have higher levels of inflammatory markers
(calprotectin, hs-CRP and systemic cytokines) com-
pared with the patients with no/mild fatigue (p¼NS
for all comparisons).
Table 3. Comparison of inflammatory markers between patients
with ulcerative colitis (UC) with high and no/mild fatigue.
UC high fatigue
(N¼ 116)
UC no/mild
fatigue
(N¼ 172) p
Calprotectin (mg/g)a 112 (27–663) 53 (17–190) <.01
hs-CRP (mg/L)b 1.40 (0.39–4.03) 1.00 (0.40–3.00) .35
IL-17A (pg/mL)c 1.79 (0.80–4.01) 0.96 (0.58–1.80) <.01
IL-6 (pg/mL)c 0.84 (0.41–2.16) 0.88 (0.44–2.11) .66
IL-1b (pg/mL)c 0.02 (0.00–0.18) 0.03 (0.00–0.30) .55
IL-10 (pg/mL)c 0.46 (0.17–0.97) 0.41 (0.21–1.06) .52
IL-8 (pg/mL)c 53 (18–1310) 73 (20–1451) .62
TNF-a (pg/mL)c 1.85 (1.54–2.89) 2.16 (1.62–2.96) .07
IL-13 (pg/mL)c 2.69 (0.28–12.03) 2.68 (0.32–13.15) .60
IFN- (pg/mL)c 6.10 (3.68–12.84) 6.04 (3.51–9.91) .50
IL-4 (pg/mL)c 0.03 (0.00–0.17) 0.02 (0.00–0.09) .11
IL-12p70 (pg/mL)c 0.20 (0.07–0.39) 0.15 (0.07–0.43) .46
All values expressed as median (IQR). Missing data: an¼ 18, bn¼ 29,
cn¼ 40.
Table 2. Comparison of clinical disease activity, anaemia, iron
deficiency, psychological distress and quality of life in patients with
ulcerative colitis (UC) with high fatigue and no/mild fatigue.
UC high
fatigue
(N¼ 116)
UC no/
mild fatigue
(N¼ 172) p
Mayo scorea 3.4 (3.1) 1.7 (2.5) <.001
Anaemia, n (%) 7 (6) 6 (3) .39
Iron deficiency, n (%)b 32 (32) 12 (19) <.001
Anxiety and
depression (HAD)a,c
12.2 (6.9) 4.9 (4.5) <.001
Quality of life (IBDQ)a,d 156 (31) 196 (21) <.001
aMean (SD).
bMissing data: high fatigue n¼ 16, no/mild fatigue n¼ 13.
cHospital Anxiety and Depression scale, total score.
dInflammatory Bowel Disease Questionnaire.
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Discussion
In this large cross-sectional study, we confirmed that
fatigue is a common problem in patients with UC.
In line with previous reports, we found psychological
distress, disease activity and female gender to be
important factors for fatigue,1,2,4–6,9,12 but also suggest
iron deficiency as an independent risk factor for high
fatigue in patients with UC. Furthermore, we demon-
strated a high prevalence of fatigue in UC patients
during deep remission and that low-grade immune
activity does not seem to be the cause of fatigue
among these patients.
Fatigue is a complex and multidimensional symptom
with both physical and mental components. Persistent
fatigue might reflect underlying somatic and/or psychi-
atric disease or might even be a side effect of medical
treatment.10 In this study, the prevalence of high fati-
gue, defined as an MFI General fatigue score 13,3 was
40% in the total study population. Moreover, 52%
among the patients with active UC and 26% in the
group of patients who fulfilled the criteria for deep
remission suffered from high fatigue. These results are
in line with a previous Nordic study.6 Even higher
prevalence of high fatigue among IBD patients with
active disease has been reported (70–75%).1,5 This dis-
crepancy might be explained by the fact that in our
study, a large proportion of the patients classified
with active disease had mild disease activity. The preva-
lence of high fatigue among patients with UC in deep
remission in our study is lower compared with previous
reports on patients with quiescent IBD.3–5 A possible
explanation is the strict criteria for deep remission used
in our study.
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Figure 3. Differences in the prevalence of high fatigue among patients with and without the independent risk factors for high fatigue: (a)
probable psychiatric disorder, (b) iron deficiency, (c) active disease and (d) female gender.
Table 4. Comparison between UC patients in deep remission
(UCR) with high and no/mild fatigue.
UCR high
fatigue
(N¼ 35)
UCR no/mild
fatigue
(N¼ 98) p
Years of age, mean
(min–max)
40 (19–66) 43 (18–73) .29
Female gender, n (%) 20 (57) 31 (32) .01
GI symptoms (GSRS)a 2.1 (0.8) 1.7 (0.6) <.01
IBS-like symptoms, n (%) 10 (29) 14 (14) .07
Anxiety and depression
(HAD)b
11.3 (6.3) 4.4 (3.9) <.001
Quality of life (IBDQ)c 178 (22) 204 (15) <.001
Anaemia, n (%) 0 (0) 2 (2) .54
Iron deficiency, n (%)d 6 (19) 7 (8) .10
aGastrointestinal symptoms (Gastrointestinal Symptom Rating Scale), mean
(SD).
bHospital Anxiety and Depression scale, total score, mean (SD).
cInflammatory Bowel Disease Questionnaire, mean (SD).
dMissing data: UCR high fatigue n¼ 3, no/mild fatigue n¼ 6.
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Psychosocial factors have been associated with fati-
gue among patients with IBD,1,4,5,8 which was con-
firmed in the present study, where high fatigue in UC
patients was associated with higher levels of anxiety
and depression and reduced health-related quality of
life. Probable psychiatric disease was identified as
an independent risk factor for high fatigue in the regres-
sion analysis, and the patients with a probable psychi-
atric disorder had higher scores on all MFI domains,
further supporting the importance of evaluating psy-
chological distress among UC patients suffering from
fatigue. This observation was, however, expected, since
symptoms included in the criteria for depressive dis-
orders, such as perceived fatigue, loss of energy, dimin-
ished interest in activity, psychomotor retardation and
reduced ability to concentrate, also are central symp-
toms in the assessment of fatigue by the MFI.38
The patients with high fatigue had higher inflamma-
tory disease activity, measured by the total Mayo score
and faecal calprotectin, compared with the patients
with no/mild fatigue, which is in agreement with previ-
ous studies.1,2,5,6,11,13 Systemic immunological activity,
measured by IL-17A, was also elevated among the
patients with high fatigue. The elevated serum levels
of IL-17A might reflect the colonic disease activity.
Previous work from our group demonstrated a correl-
ation between levels of IL-17A in serum and clinical
disease activity in UC patients.39 The level of fatigue
among patients with IBD has been reported to be simi-
lar to that in patients with other chronic inflammatory
diseases, such as rheumatic diseases and cancer,3 and
systemic inflammatory activity (IL-1, IL-6, IL-8 and
TNF-a) has been suggested to be a common link
between fatigue, pain and psychological distress.16
Our patients with high fatigue had increased levels of
IL-17A, but no other serum cytokines were elevated.
This result indicates that systemic immune activity
might contribute to generation of fatigue among
patients with UC. However, the increased colonic
inflammation observed among the patients might also
affect the central nervous system directly through the
autonomous nerve system, that is, the brain–gut axis,
which has been suggested to be a possible pathway for
fatigue.16
Anaemia and iron deficiency are possible contribut-
ing factors to fatigue. Iron is essential for the produc-
tion of red blood cells,14 but is also important for
normal function of the cells of the brain.40 Therefore,
iron deficiency might affect both cognitive and emo-
tional factors.40 Anaemia has been correlated with fati-
gue in patients with IBD in some studies,2,4 while others
found no correlation.3,5,6,13 We observed no difference
comparing anaemia among UC patients with high fati-
gue and no/mild fatigue, but these data must be
interpreted with caution, since the prevalence of anae-
mia was very low (5%). Further, the cut-off for anae-
mia is the lower limit of the normal range, which means
that a proportion of the patients might have had
reduced haemoglobin levels compared with their
normal level without fulfilling the criteria for anaemia.
However, the present study shows that patients with
UC with concomitant iron deficiency have higher
levels of fatigue compared with patients without iron
deficiency. Iron deficiency was also an independent risk
factor for high fatigue. In contrast, three previous stu-
dies found no correlation between iron deficiency and
fatigue in IBD patients.6,12,13 A possible explanation
for these conflicting data might be different definitions
of iron deficiency and the use of different serological
markers for iron deficiency. In the present study, the
patients were thoroughly examined to identify active
disease (faecal calprotectin and endoscopy), and soluble
transferrin receptor and transferrin saturation were
used in combination with levels of ferritin to classify
patients as iron deficient or not in accordance with
ECCO guidelines.14 Moreover, in this study, patients
with ferritin> 100 mg/L had lower levels of fatigue com-
pared with those who had ferritin< 30 mg/L, further
supporting the idea that iron deficiency seems to be of
importance for the generation of fatigue. However,
from the results of this cross-sectional study, it is not
possible to conclude that fatigue among these patients
would be improved by iron supplement treatment.
The majority of previous studies report higher levels
of fatigue among female IBD patients.1,4, 6,11 In this
study, female gender was more prevalent among the
UC patients with high fatigue and was also identified
as an independent risk factor for high fatigue. This
result is also in line with studies on chronic fatigue syn-
drome, which is more prevalent among women.41
Possible explanations for the gender differences are hor-
monal and biopsychosocial factors (including stress-
induced immunological alterations).41
Although several independent factors associated with
high fatigue were identified by our logistic regression
analysis, only about a third of the variance in fatigue
could be explained by factors evaluated in this study,
which points to the complexity of evaluating fatigue.
Our study demonstrates that patients with psycho-
logical distress, active disease and iron deficiency report
higher levels of fatigue in all MFI domains. Similar
observations have been reported in IBD patients with
active disease.4–6 Additionally, in the study by
Goldenberg et al.,13 IBD patients with iron deficiency
tended to have higher levels of mental fatigue, but no
difference was observed in the other domains of fatigue.
The observation that iron deficiency might affect
cognitive components is interesting, since a recent
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meta-analysis on non-anaemic iron-deficient patients
reported that iron supplementation can improve fati-
gue, prostration and concentration but not exercise
tolerance.42
The prevalence of high fatigue (26%) among the
patients with UC in deep remission is, however, evi-
dently high, since the definition of high fatigue
(MFI General fatigue 13) is based on the 95th per-
centile of healthy controls in a previous Dutch study.3
To understand why a large proportion of the UC
patients without apparent disease activity experienced
severe fatigue, we further analysed these patients and
found similar results as in the total study population
concerning psychological distress, gender and iron defi-
ciency. Additionally, the patients in deep remission
with high fatigue reported more gastrointestinal
symptoms, and IBS-like symptoms tended to be more
prevalent among the patients with high fatigue com-
pared with patients with no/mild fatigue. Our results
are in line with the results from a Norwegian study
that reported higher levels of fatigue among UC
patients in clinical remission with IBS-like symptoms
compared with patients in remission without IBS-like
symptoms.23 These results could be interpreted as a sign
of low-grade inflammatory disease activity, but this
could not be confirmed, since the patients in deep
remission with and without high fatigue had similar
levels of colonic inflammation and systemic immune
activity.
Strengths of the present study are the large cohort
of UC patients and the thorough investigation with
endoscopy and inflammatory markers in stool
and blood samples in order to evaluate on-going
inflammatory activity. We decided not to include
patients with Crohn’s disease, as it is more difficult to
verify that these patients are in deep remission com-
pared with patients with UC. Another advantage is
that we evaluated the potential relationship between
fatigue and systemic immune activity. Further strengths
are the careful evaluation of the patients’ iron
status with multiple serological markers combined
with the cautious investigation of inflammatory activ-
ity in accordance with recent ECCO guidelines.14
A limitation of the study is the cross-sectional design,
which makes it impossible to evaluate the causes and
consequences of high fatigue in a longitudinal perspec-
tive. Moreover, the study did not include healthy
controls.
To conclude, high fatigue is common among UC
patients with active disease as well as among patients
in deep remission. Iron deficiency seems to be of
importance for fatigue, and we confirm that psycho-
logical distress, disease activity and female gender are
associated with high fatigue. However, low-grade
inflammatory activity does not seem to be the cause
of fatigue among UC patients in deep remission.
Prospective and comparative studies are needed to fur-
ther evaluate the mechanisms behind fatigue in patients
with UC and to determine appropriate treatments for
this category of patients in order to improve their qual-
ity of life.
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